Document is current

Article History

Received: 9 January 2024

Revised: 22 May 2024

Accepted: 27 June 2024

First Online: 15 August 2024

Compliance with ethical standards

:

: The scientific guarantor of this publication is Michelle S. Ginsberg.

: Dr. Mayoral received funding from Canon Spain to attend the Annual Meeting of the Radiological Society of North America (RSNA) in 2023 to present an oral communication on the results of this manuscript. Dr. Adusumilli declares research funding from ATARA Biotherapeutics; Scientific Advisory Board Member and Consultant for ATARA Biotherapeutics, Bayer, Bio4T2, Carisma Therapeutics, Imugene, ImmPactBio, Johnston & Johnston, Orion pharma, Outpace Bio; Patents, royalties, and intellectual property on mesothelin-targeted CAR and other T-cell therapies, which have been licensed to ATARA Biotherapeutics, issued patent method for detection of cancer cells using virus, and pending patent applications on PD-1 dominant negative receptor, wireless pulse-oximetry device, and on an ex vivo malignant pleural effusion culture system. Memorial Sloan Kettering Cancer Center has licensed intellectual property related to mesothelin-targeted CARs and T-cell therapies to ATARA Biotherapeutics and has associated financial interests. Dr. Adusumilli’s laboratory work is supported by grants from the National Institutes of Health (P30 CA008748, R01 CA236615-01, and R01 CA235667), the U.S. Department of Defense (BC132124, LC160212, CA170630, CA180889, and CA200437), the Batishwa Fellowship, the Comedy vs. Cancer Award, the Dalle Pezze Foundation, the Derfner Foundation, the Esophageal Cancer Education Fund, the Geoffrey Beene Foundation, the Memorial Sloan Kettering Technology Development Fund, the Miner Fund for Mesothelioma Research, Mr. William H. Goodwin and Alice Goodwin, the Commonwealth Foundation for Cancer Research, and the Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center. P.S.A.’s laboratory receives research support from Atara Biotherapeutics. Dr. Rusch’s conflicts of interest related to the content of this manuscript are being a member of the DSMC for the MARS II trial and RAMON trial, Cancer Research UK (unpaid), and being co-chair of the Thoracic Malignancy Steering Committee, NIH (payment for meeting preparation). Dr. Zauderer has received in the last 3 years consulting fees from Curis, Ikena, Takeda, GlaxoSmithKline, and Novocure and honoraria for CME content from PER, Medscape, and Research to Practice. Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, MedImmune, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis, and Atara for research conducted by Dr. Zauderer. Dr. Zauderer serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated.

: Dr. Tan performed the statistical analysis of this study.

: Written informed consent was waived by the Institutional Review Board.

: Institutional Review Board approval was obtained.

: None of the study subjects or cohorts have been previously reported; there are no overlaps with any prior studies.

: